Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer

•The efficacy of ICIs varies among NSCLC patients who have received Abx treatment or not.•Concomitant Abx treatment is correlated with worse survival benefits from ICIs therapies.•Concomitant Abx treatment is not associated with the occurrence and grades of irAEs. Gut microbiome plays a dominant rol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-04, Vol.130, p.10-17
Hauptverfasser:	Zhao, Sha, Gao, Guanghui, Li, Wei, Li, Xuefei, Zhao, Chao, Jiang, Tao, Jia, Yijun, He, Yayi, Li, Aiwu, Su, Chunxia, Ren, Shengxiang, Chen, Xiaoxia, Zhou, Caicun
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anti-Bacterial Agents - therapeutic use Antibiotics Antibodies, Monoclonal - therapeutic use Antineoplastic Agents, Immunological - therapeutic use B7-H1 Antigen - antagonists & inhibitors Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - epidemiology Carcinoma, Non-Small-Cell Lung - mortality China - epidemiology Drug Therapy, Combination Dysbiosis - drug therapy Dysbiosis - epidemiology Female Humans Immune checkpoint inhibitors Immunotherapy - methods Lung Neoplasms - drug therapy Lung Neoplasms - epidemiology Lung Neoplasms - mortality Male Middle Aged Non-small cell lung cancer PD-1/PD-L1 Programmed Cell Death 1 Receptor - antagonists & inhibitors Retrospective Studies Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!